T Verstraeten

Summary

Affiliation: GlaxoSmithKline Biologicals
Country: Belgium

Publications

  1. ncbi Enhancing vaccine safety surveillance: a capture-recapture analysis of intussusception after rotavirus vaccination
    T Verstraeten
    Epidemic Intelligence Service, Division of Applied Public Health Training, Epidemiology Program Office, Centers for Disease Control and Prevention, Atlanta, GA, USA
    Am J Epidemiol 154:1006-12. 2001
  2. ncbi Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines
    Thomas Verstraeten
    GlaxoSmithKline Biologicals, Rixensart, Belgium
    Vaccine 26:6630-8. 2008
  3. ncbi Vaccine safety surveillance using large linked databases: opportunities, hazards and proposed guidelines
    Thomas Verstraeten
    GlaxoSmithKline Biologicals, Rixensart, Belgium
    Expert Rev Vaccines 2:21-9. 2003
  4. ncbi A retrospective cohort study of the association of varicella vaccine failure with asthma, steroid use, age at vaccination, and measles-mumps-rubella vaccination
    Thomas Verstraeten
    Epidemic Intelligence Service Program, Epidemiology Program Office, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
    Pediatrics 112:e98-103. 2003
  5. ncbi Immunity to tetanus is protective against the development of multiple sclerosis
    T Verstraeten
    Epidemic Intelligence Service EIS Program, Epidemiology Program Office, Centers for Disease Control and Prevention, Altanta, GA, USA
    Med Hypotheses 65:966-9. 2005
  6. ncbi Safety of thimerosal-containing vaccines: a two-phased study of computerized health maintenance organization databases
    Thomas Verstraeten
    Epidemic Intelligence Service Program, Epidemiology Program Office, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    Pediatrics 112:1039-48. 2003
  7. ncbi Vaccinations and risk of central nervous system demyelinating diseases in adults
    Frank Destefano
    National Immunization Program, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    Arch Neurol 60:504-9. 2003
  8. ncbi Burden of rotavirus disease in European Union countries
    Montse Soriano-Gabarro
    GlaxoSmithKline Biologicals, Rixensart, Belgium
    Pediatr Infect Dis J 25:S7-S11. 2006
  9. ncbi Thimerosal, the Centers for Disease Control and Prevention, and GlaxoSmithKline
    Thomas Verstraeten
    Pediatrics 113:932. 2004
  10. ncbi Rotavirus serotype G9 is associated with more-severe disease in Latin America
    A C Linhares
    Instituto Evandro Chagas, Secretaria de Vigilância em Saúde, Ministerio da Saude, Belem, Brazil
    Clin Infect Dis 43:312-4. 2006

Detail Information

Publications12

  1. ncbi Enhancing vaccine safety surveillance: a capture-recapture analysis of intussusception after rotavirus vaccination
    T Verstraeten
    Epidemic Intelligence Service, Division of Applied Public Health Training, Epidemiology Program Office, Centers for Disease Control and Prevention, Atlanta, GA, USA
    Am J Epidemiol 154:1006-12. 2001
    ..7 and 4.4, respectively) were comparable with those reported in the two studies. Linkage of VAERS to complimentary data sources may permit more timely postmarketing assessment of vaccine safety...
  2. ncbi Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines
    Thomas Verstraeten
    GlaxoSmithKline Biologicals, Rixensart, Belgium
    Vaccine 26:6630-8. 2008
    ....
  3. ncbi Vaccine safety surveillance using large linked databases: opportunities, hazards and proposed guidelines
    Thomas Verstraeten
    GlaxoSmithKline Biologicals, Rixensart, Belgium
    Expert Rev Vaccines 2:21-9. 2003
    ..We also offer our opinion on the future use of large linked databases for vaccine safety surveillance purposes...
  4. ncbi A retrospective cohort study of the association of varicella vaccine failure with asthma, steroid use, age at vaccination, and measles-mumps-rubella vaccination
    Thomas Verstraeten
    Epidemic Intelligence Service Program, Epidemiology Program Office, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
    Pediatrics 112:e98-103. 2003
    ..We assessed the association of varicella breakthrough with asthma, steroids, age at varicella vaccination, and timing of measles-mumps-rubella (MMR) vaccination...
  5. ncbi Immunity to tetanus is protective against the development of multiple sclerosis
    T Verstraeten
    Epidemic Intelligence Service EIS Program, Epidemiology Program Office, Centers for Disease Control and Prevention, Altanta, GA, USA
    Med Hypotheses 65:966-9. 2005
    ..Laboratory evidence could be sought by testing the effect of tetanus toxoid on experimental allergic encephalomyelitis, the experimental animal model of MS...
  6. ncbi Safety of thimerosal-containing vaccines: a two-phased study of computerized health maintenance organization databases
    Thomas Verstraeten
    Epidemic Intelligence Service Program, Epidemiology Program Office, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    Pediatrics 112:1039-48. 2003
    ..Conflicting results were found at different HMOs for certain outcomes. For resolving the conflicting findings, studies with uniform neurodevelopmental assessments of children with a range of cumulative thimerosal exposures are needed...
  7. ncbi Vaccinations and risk of central nervous system demyelinating diseases in adults
    Frank Destefano
    National Immunization Program, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    Arch Neurol 60:504-9. 2003
    ..Several case reports of the onset or exacerbation of multiple sclerosis or other demyelinating conditions shortly after vaccination have suggested that vaccines may increase the risk of demyelinating diseases...
  8. ncbi Burden of rotavirus disease in European Union countries
    Montse Soriano-Gabarro
    GlaxoSmithKline Biologicals, Rixensart, Belgium
    Pediatr Infect Dis J 25:S7-S11. 2006
    ..With the introduction of new rotavirus vaccines in sight, rotavirus gastroenteritis may be regarded as the single most frequent vaccine-preventable disease among children in the EU...
  9. ncbi Thimerosal, the Centers for Disease Control and Prevention, and GlaxoSmithKline
    Thomas Verstraeten
    Pediatrics 113:932. 2004
  10. ncbi Rotavirus serotype G9 is associated with more-severe disease in Latin America
    A C Linhares
    Instituto Evandro Chagas, Secretaria de Vigilância em Saúde, Ministerio da Saude, Belem, Brazil
    Clin Infect Dis 43:312-4. 2006
    ..Thus, demonstration of efficacy against G9 will be an important asset of any rotavirus vaccine to be introduced into a Latin American country or any country where G9 has been shown to be prevalent...
  11. ncbi The epidemiology of paediatric intussusception in Singapore: 1997 to 2004
    Irving Charles Boudville
    GlaxoSmithKline Biologicals, Singapore
    Ann Acad Med Singapore 35:674-9. 2006
    ..Post-marketing surveillance is also important, and requires the availability of local baseline epidemiology data on IS...
  12. ncbi Four and one-half-year follow-up of the effectiveness of diphtheria-tetanus toxoids-acellular pertussis/Haemophilus influenzae type b and diphtheria-tetanus toxoids-acellular pertussis-inactivated poliovirus/H. influenzae type b combination vaccines in Ge
    Helen Kalies
    Institute for Social Pediatrics and Adolescent Medicine, Ludwig Maxilimilians University, Heiglhofstrasse 63, 81377 Munich, Germany
    Pediatr Infect Dis J 23:944-50. 2004
    ..A study in Germany based on approximately 2 years of follow-up, estimated vaccine effectiveness (VE) of DTaP/Hib and DTaP-inactivated poliovirus/Hib combination vaccines against invasive Hib disease to be high...